This nanoagonist, designed to respond to the TME, utilized PC6AB's membranolytic activity to induce tumor cell death, thereby providing a chemotherapy effect, while MnP activated immune cells and triggered the STING pathway, generating an immunotherapy effect. Here, STING1 is linked to neoplasm.